Aegerion Pharma Takes Third Shot at IPO

Aegerion Pharmaceuticals Inc., a Bridgewater, N.J.-based drug developer focused on cardiovascular and metabolic diseases, has re-filed for an $86.25 million IPO. This the the company’s third IPO filing, having twice before filed and withdrawn due to “market conditions.”

Leerink Swan and Lazard Capital Markets are serving as co-lead underwriters.

Aegerion has raised over $44 million in total VC funding, from firms like Index Ventures, Advent International, Alta Partners, Scheer & Co. and MVM Life Science Partners.

Leave a Reply

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget